Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00172081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00172081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
April 27, 2000
Completion date
November 7, 2003
Enrollment
2,532 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis